Company intelligence / Profile preview

Brevel

Shekef, South District, Israelbrevel.co.il ↗

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Brevel has developed and commercialized a proprietary fermentation process to produce neutral-flavored, sustainable microalgae protein at scale. Its first plant with 5,000-liter capacity opened in 2024; the company plans further global expansion through joint ventures. The technology enables cost parity with soy and pea proteins while providing additional co-products such as polar lipids and fiber. Initial products are expected to launch commercially in Q1 2025.

Modalities: Protein (microalgae-derived)EmulsifiersNutritional boosters
Industry: Food & Nutrition

Partnerships

Two undisclosed strategic partners in the dairy and beverage sectors (> $2B companies)Joint venture partnerships planned/underway in US, Europe, Asia for large-scale manufacturing facilities

Beyond the preview

Go deeper on Brevel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Brevel.

Explore the full profile